50 results about "Recombinant virus vaccine" patented technology

The present inventors developed 5a / 2a intergenotypic recombinants in which the JFH1 structural genes (Core, E1 and E2), p7 and all of or part of NS2 were replaced by the corresponding genes of the genotype 5a reference strain SA13. Compared to the J6 / JFH control virus, after transfection of in vitro transcripts in Huh7.5 cells, production of infectious viruses was delayed. However, in subsequent viral passages efficient spread of infection and HCV RNA titers as high as for J6 / JFH were obtained. Infectivity titers were at all time points analyzed comparable to J6 / JFH control virus. Sequence analysis of recovered 5a / 2a recombinants from 2 serial passages and subsequent reverse genetic studies revealed adaptive mutations in p7, NS2 and / or NS3. Infectivity of the 5a / 2a viruses was CD81 and SR-BI dependant, and the recombinant viruses could be neutralized by chronic phase sera from patients infected with genotype 5a. Conclusion: The developed 5a / 2a viruses provide a robust in vitro tool for research in HCV genotype 5, including vaccine studies and functional analyses of an increasingly important genotype in South Africa and Europe.

The invention discloses an adenovirus vector vaccine for preventing SARS-CoV-2 infection. The vaccine comprises a nucleic acid sequence as shown in SEQ ID NO: 1. According to a plurality of embodiments of the invention, the S protein nucleic acid sequence contained in the vaccine is easy to express in human cells, and generation of more S proteins can be induced, so the vaccine is expected to be used as a recombinant virus vaccine for preventing SARS-CoV-2 infection. According to a plurality of embodiments of the invention, the vaccine has good security.

The invention relates to a virus vaccine A-NDV-LX / 14 for a newcastle disease, which is a recombinant of expressed genes VII F and HN, and the preservation number is CGMCCNO: 3844. After two weeks of the constructed virus A-NDV-LX / 14 immunity test on chicken, the average potency of the serum HI is 27. After four days of eliminating toxic material with immune group LaSota, the virus isolation ratesof SPF chicken laryngotracheal and cloacal swab samples are 10 percent and 30 percent respectively, and the virus isolation rates of chicken laryngotracheal and cloacal swab samples are 40 percent and 20 percent respectively. After four days of eliminating toxic material with immune group V4, the virus isolation rates of SPF chicken laryngotracheal and cloacal swab samples are 30 percent and 10 percent respectively, and the virus isolation rates of chicken laryngotracheal and cloacal swab samples are 30 percent and 20 percent respectively. Compared with traditional vaccine, more effective immune protection can be provided by the recombinant virus vaccine.

The invention provides a preparation method of a recombinant Newcastle disease virus vaccine strain expressing African swine fever virus p72 protein and the recombinant Newcastle disease virus vaccine strain. The method of the present invention includes: constructing a recombinant transcription plasmid in which the p72 gene of African swine fever virus (ASFV) is inserted, constructing a transcription auxiliary plasmid system, and co-transfecting the above transcription plasmid and the transcription auxiliary plasmid into the attenuated Newcastle disease strain to be able to replicate The host cell BHK‑21 was rescued to obtain the recombinant virus strain. The vaccine strain expressing the African swine fever virus p72 protein prepared by the invention has important reserve and strategic significance in the prevention and control of the animal disease, and can be used in the treatment and prevention of the African swine fever virus.

The invention discloses a herpes simplex virus type 2 (HSV-2) genetic recombinant attenuated live vaccine and a preparation method thereof. US2, US3, US4 and US5 genes in a genome are knocked out. The method comprises the following steps of: separating and identifying vesicle liquid of a patient who suffers from oral herpes and genital herpes and has obvious vesicles to obtain wild type HSV-1 and HSV-2; performing amplifying culture, and extracting a virus complete genome; transfecting Vero cells by using a shuttle vector containing a fluorescent expressed gene and 700bp to 2,000bp homologous flanking sequences on the left and right sides of an HSV gene which is prepared to be knocked out; and picking recombinant virus out under a fluorescent microscope by using one or more fluorescent protein genes as markers, and performing plaque purification to obtain the needed recombinant attenuated live vaccine. The vaccine effectively induces mucosal and humoral immune response of organisms, so that the morbidity of people is reduced; and cellular immune response is excited, so that the infected virus can be cleared, and the relapse and spreading of herpes are controlled.